Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

4 structures for O94953

Entry ID Method Resolution Chain Position Source
4LXL X-ray 187 A A 1-348 PDB
4UC4 X-ray 256 A A/B 917-1031 PDB
7JM5 X-ray 270 A A/B 1-366 PDB
AF-O94953-F1 Predicted AlphaFoldDB

6 variants for O94953

Variant ID(s) Position Change Description Diseaes Association Provenance
VAR_085967 220 L>P MRD65 [UniProt] Yes UniProt
VAR_085968 222 R>W MRD65 [UniProt] Yes UniProt
VAR_085969 768 H>R MRD65 [UniProt] Yes UniProt
VAR_085970 1095 P>L MRD65; unknown pathological significance [UniProt] Yes UniProt
rs11667206
VAR_026223
29 N>T No UniProt
dbSNP
VAR_026224
rs2620836
710 K>E No UniProt
dbSNP

1 associated diseases with O94953

[MIM: 619320]: Intellectual developmental disorder, autosomal dominant 65 (MRD65)

An autosomal dominant form of intellectual disability, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD65 is characterized by delayed motor and speech acquisition, variably impaired intellectual development, behavioral abnormalities, and dysmorphic facial features. Additional variable features include feeding difficulties, hypotonia, and seizures. {ECO:0000269|PubMed:33232677}. Note=The disease is caused by variants affecting the gene represented in this entry.

Without disease ID
  • An autosomal dominant form of intellectual disability, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD65 is characterized by delayed motor and speech acquisition, variably impaired intellectual development, behavioral abnormalities, and dysmorphic facial features. Additional variable features include feeding difficulties, hypotonia, and seizures. {ECO:0000269|PubMed:33232677}. Note=The disease is caused by variants affecting the gene represented in this entry.

10 regional properties for O94953

Type Name Position InterPro Accession
domain Zinc finger, PHD-type 731 - 789 IPR001965-1
domain Zinc finger, PHD-type 851 - 907 IPR001965-2
domain Tudor domain 917 - 974 IPR002999-1
domain Tudor domain 975 - 1031 IPR002999-2
domain JmjC domain 143 - 309 IPR003347
domain JmjN domain 14 - 57 IPR003349
domain Extended PHD (ePHD) domain 794 - 907 IPR034732
domain Lysine-specific demethylase 4-like, Tudor domain 922 - 956 IPR040477-1
domain Lysine-specific demethylase 4-like, Tudor domain 980 - 1014 IPR040477-2
domain Lysine-specific demethylase 4B, first Tudor domain 919 - 972 IPR047483

Functions

Description
EC Number 1.14.11.66 With 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors
Subcellular Localization
  • Nucleus
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

2 GO annotations of cellular component

Name Definition
nucleoplasm That part of the nuclear content other than the chromosomes or the nucleolus.
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

5 GO annotations of molecular function

Name Definition
histone demethylase activity Catalysis of the removal of a methyl group from a histone.
histone H3-methyl-lysine-36 demethylase activity Catalysis of the removal of a methyl group from a modified lysine residue at position 36 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.
histone H3-methyl-lysine-9 demethylase activity Catalysis of the removal of a methyl group from a modified lysine residue at position 9 of the histone H3 protein.
histone H3-tri/dimethyl-lysine-9 demethylase activity Catalysis of the removal of a methyl group from a tri or a dimethyl-lysine residue at position 9 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.
metal ion binding Binding to a metal ion.

4 GO annotations of biological process

Name Definition
brain development The process whose specific outcome is the progression of the brain over time, from its formation to the mature structure. Brain development begins with patterning events in the neural tube and ends with the mature structure that is the center of thought and emotion. The brain is responsible for the coordination and control of bodily activities and the interpretation of information from the senses (sight, hearing, smell, etc.).
chromatin remodeling A dynamic process of chromatin reorganization resulting in changes to chromatin structure. These changes allow DNA metabolic processes such as transcriptional regulation, DNA recombination, DNA repair, and DNA replication.
histone H3-K36 demethylation The modification of histone H3 by the removal of a methyl group from lysine at position 36 of the histone.
histone H3-K9 demethylation The modification of histone H3 by the removal of a methyl group from lysine at position 9 of the histone.

4 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q9BY66 KDM5D Lysine-specific demethylase 5D Homo sapiens (Human) PR
O75164 KDM4A Lysine-specific demethylase 4A Homo sapiens (Human) PR
Q3U2K5 Kdm4d Lysine-specific demethylase 4D Mus musculus (Mouse) PR
Q8BW72 Kdm4a Lysine-specific demethylase 4A Mus musculus (Mouse) PR
10 20 30 40 50 60
MGSEDHGAQN PSCKIMTFRP TMEEFKDFNK YVAYIESQGA HRAGLAKIIP PKEWKPRQTY
70 80 90 100 110 120
DDIDDVVIPA PIQQVVTGQS GLFTQYNIQK KAMTVGEYRR LANSEKYCTP RHQDFDDLER
130 140 150 160 170 180
KYWKNLTFVS PIYGADISGS LYDDDVAQWN IGSLRTILDM VERECGTIIE GVNTPYLYFG
190 200 210 220 230 240
MWKTTFAWHT EDMDLYSINY LHFGEPKSWY AIPPEHGKRL ERLAIGFFPG SSQGCDAFLR
250 260 270 280 290 300
HKMTLISPII LKKYGIPFSR ITQEAGEFMI TFPYGYHAGF NHGFNCAEST NFATLRWIDY
310 320 330 340 350 360
GKVATQCTCR KDMVKISMDV FVRILQPERY ELWKQGKDLT VLDHTRPTAL TSPELSSWSA
370 380 390 400 410 420
SRASLKAKLL RRSHRKRSQP KKPKPEDPKF PGEGTAGAAL LEEAGGSVKE EAGPEVDPEE
430 440 450 460 470 480
EEEEPQPLPH GREAEGAEED GRGKLRPTKA KSERKKKSFG LLPPQLPPPP AHFPSEEALW
490 500 510 520 530 540
LPSPLEPPVL GPGPAAMEES PLPAPLNVVP PEVPSEELEA KPRPIIPMLY VVPRPGKAAF
550 560 570 580 590 600
NQEHVSCQQA FEHFAQKGPT WKEPVSPMEL TGPEDGAASS GAGRMETKAR AGEGQAPSTF
610 620 630 640 650 660
SKLKMEIKKS RRHPLGRPPT RSPLSVVKQE ASSDEEASPF SGEEDVSDPD ALRPLLSLQW
670 680 690 700 710 720
KNRAASFQAE RKFNAAAART EPYCAICTLF YPYCQALQTE KEAPIASLGK GCPATLPSKS
730 740 750 760 770 780
RQKTRPLIPE MCFTSGGENT EPLPANSYIG DDGTSPLIAC GKCCLQVHAS CYGIRPELVN
790 800 810 820 830 840
EGWTCSRCAA HAWTAECCLC NLRGGALQMT TDRRWIHVIC AIAVPEARFL NVIERHPVDI
850 860 870 880 890 900
SAIPEQRWKL KCVYCRKRMK KVSGACIQCS YEHCSTSFHV TCAHAAGVLM EPDDWPYVVS
910 920 930 940 950 960
ITCLKHKSGG HAVQLLRAVS LGQVVITKNR NGLYYRCRVI GAASQTCYEV NFDDGSYSDN
970 980 990 1000 1010 1020
LYPESITSRD CVQLGPPSEG ELVELRWTDG NLYKAKFISS VTSHIYQVEF EDGSQLTVKR
1030 1040 1050 1060 1070 1080
GDIFTLEEEL PKRVRSRLSL STGAPQEPAF SGEEAKAAKR PRVGTPLATE DSGRSQDYVA
1090
FVESLLQVQG RPGAPF